Editas Medicine Correlations

EDIT Stock

USD 1.90 0.00 0.00%

The current 90-days correlation between Editas Medicine and Crispr Therapeutics AG is -0.02 (i.e., Good diversification). The correlation of Editas Medicine is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Editas Medicine Correlation With Market

Good diversification

The correlation between Editas Medicine and DJI is -0.04 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Editas Medicine and DJI in the same portfolio, assuming nothing else is changed.

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Editas Medicine. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Editas Stock please use our How to Invest in Editas Medicine guide.

Moving together with Editas Stock

0.69	KURA	Kura Oncology	Pair Corr
0.62	ABOS	Acumen Pharmaceuticals	Pair Corr
0.67	ADTX	Aditxt Inc	Pair Corr
0.73	ANAB	AnaptysBio	Pair Corr
0.7	STRO	Sutro Biopharma	Pair Corr
0.64	TCRX	Tscan Therapeutics	Pair Corr
0.75	CRSP	Crispr Therapeutics	Pair Corr
0.61	DAWN	Day One Biopharmaceu	Pair Corr

Moving against Editas Stock

0.54	XFOR	X4 Pharmaceuticals	Pair Corr
0.53	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.47	GANX	Gain Therapeutics	Pair Corr
0.43	A	Agilent Technologies Earnings Call Today	Pair Corr
0.41	FENC	Fennec Pharmaceuticals	Pair Corr
0.39	LTRN	Lantern Pharma	Pair Corr
0.38	NAMSW	NewAmsterdam Pharma	Pair Corr
0.35	OPT	Opthea Earnings Call Today	Pair Corr
0.34	CUE	Cue Biopharma	Pair Corr
0.33	PHGE	Biomx Inc	Pair Corr
0.73	CGTX	Cognition Therapeutics	Pair Corr
0.44	DBVT	DBV Technologies Earnings Call This Week	Pair Corr
0.44	EMBC	Embecta Corp	Pair Corr
0.35	CPRX	Catalyst Pharmaceuticals Earnings Call Today	Pair Corr
0.64	SSNLF	Samsung Electronics	Pair Corr
0.46	OBI	Ondine Biomedical	Pair Corr
0.4	ADUS	Addus HomeCare	Pair Corr
0.38	PTITF	PT Indosat Tbk	Pair Corr

Related Correlations Analysis

	BEAM	CRSP	CRBU	VERV	NTLA	PRME	VRTX	DNA	ALLO	SANA
BEAM		0.31	-0.21	0.34	0.07	-0.06	0.37	0.21	0.26	-0.07	BEAM
CRSP	0.31		0.52	0.05	0.75	0.65	0.57	-0.18	0.67	-0.01	CRSP
CRBU	-0.21	0.52		-0.6	0.9	0.68	0.0	-0.65	0.58	-0.44	CRBU
VERV	0.34	0.05	-0.6		-0.46	-0.27	0.39	0.92	-0.3	0.46	VERV
NTLA	0.07	0.75	0.9	-0.46		0.76	0.21	-0.57	0.73	-0.45	NTLA
PRME	-0.06	0.65	0.68	-0.27	0.76		-0.02	-0.36	0.8	-0.12	PRME
VRTX	0.37	0.57	0.0	0.39	0.21	-0.02		0.23	-0.01	0.26	VRTX
DNA	0.21	-0.18	-0.65	0.92	-0.57	-0.36	0.23		-0.41	0.41	DNA
ALLO	0.26	0.67	0.58	-0.3	0.73	0.8	-0.01	-0.41		-0.19	ALLO
SANA	-0.07	-0.01	-0.44	0.46	-0.45	-0.12	0.26	0.41	-0.19		SANA
	BEAM	CRSP	CRBU	VERV	NTLA	PRME	VRTX	DNA	ALLO	SANA

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

DNA	+ 0.92	VERV
NTLA	+ 0.9	CRBU
ALLO	+ 0.8	PRME
PRME	+ 0.76	NTLA
NTLA	+ 0.75	CRSP
ALLO	+ 0.73	NTLA

High negative correlations

DNA	- 0.65	CRBU
VERV	- 0.6	CRBU
DNA	- 0.57	NTLA
NTLA	- 0.46	VERV
SANA	- 0.45	NTLA
SANA	- 0.44	CRBU

Risk-Adjusted Indicators

There is a big difference between Editas Stock performing well and Editas Medicine Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Editas Medicine's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
BEAM	3.35	0.46	0.11	(1.64)	3.51	(3.67)	8.04	(7.45)	21.42
CRSP	2.88	(0.03)	0.00	(0.05)	0.00	0.00	6.48	(4.98)	19.32
CRBU	3.00	(0.64)	0.00	(1.54)	0.00	0.00	8.22	(7.09)	17.35
VERV	5.44	0.76	0.15	0.50	4.82	(6.53)	11.24	(7.99)	36.90
NTLA	3.59	(0.33)	0.00	(0.25)	0.00	0.00	7.84	(7.15)	22.98
PRME	4.17	(0.16)	0.00	(0.12)	0.00	0.00	10.03	(6.90)	19.38
VRTX	1.38	0.06	0.02	(0.60)	2.64	(1.29)	2.57	(3.14)	13.94
DNA	6.27	1.00	0.16	0.38	6.09	(7.70)	13.55	(9.41)	36.96
ALLO	5.03	0.20	0.04	0.68	5.02	(6.85)	8.99	(8.45)	57.76
SANA	8.05	1.35	0.19	0.49	6.39	(11.15)	12.46	(11.88)	176.41

Editas Medicine Corporate Management

Bruce Eaton	Exec Officer	Profile
Cristi Barnett	Corporate Relations	Profile
Charlene JD	Executive Counsel	Profile
Michelle Robertson	Principal CFO	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC